Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacodynamics of QBKPN in Healthy Volunteers
NCT02897999Phase 1Withdrawn
- Sponsor
- Qu Biologics
- Start
- Sep 2016
- Primary completion
- Feb 2017
- Modality
- Prophylactic Vaccines, Microbiome Therapeutics, Therapeutic Vaccines
01
Overview
Phase 1, randomised, double-blind trial of QBKPN in lung cancer, chronic obstructive pulmonary disease (COPD), asthma and 1 more (10 cohorts), sponsored by Qu Biologics. Primary endpoint: Incidence of Treatment-Emergent Adverse events at 2 weeks. Planned start Sep 2016; status: withdrawn.
02
Drugs
QBKPN
03
Conditions
lung cancerchronic obstructive pulmonary disease (COPD)asthmarespiratory tract infection (RTI)
Beyond the preview
Go deeper on NCT02897999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02897999.